NASDAQ:MDCO - The Medicines Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$84.90
+0.30 (1.20%)
Get New The Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDCO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDCO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for The Medicines in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $84.90.
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in The Medicines. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/22/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/20/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$78.00 ➝ $85.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
11/26/2019Chardan CapitalDowngradeBuy ➝ NeutralLow
i
Rating by Gbola Amusa at Chardan Capital
11/25/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00Low
i
Rating by Gbola Amusa at Chardan Capital
11/25/2019OppenheimerDowngradeOutperform ➝ Hold$68.00 ➝ $85.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/25/2019Robert W. BairdDowngradeOutperform ➝ Neutral$100.00 ➝ $85.00Medium
i
11/25/2019CowenReiterated RatingBuy$60.00Low
i
Rating by Chris Shibutani at Cowen Inc
11/20/2019CitigroupReiterated RatingHold$59.00High
i
Rating by Joel Beatty at Citigroup Inc.
11/19/2019Chardan CapitalReiterated RatingBuy$100.00Low
i
Rating by Gbola Amusa at Chardan Capital
11/18/2019CowenReiterated RatingBuy$60.00High
i
Rating by Chris Shibutani at Cowen Inc
10/10/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$44.00 ➝ $50.00High
i
10/2/2019B. RileyBoost Price TargetBuy$74.00 ➝ $95.00Low
i
Rating by Mayank Mamtani at B. Riley
9/17/2019CitigroupDowngradeBuy ➝ Neutral$55.00Low
i
9/3/2019Roth CapitalSet Price TargetBuy$72.00Low
i
Rating by Yasmeen Rahimi at Roth Capital
9/3/2019SVB LeerinkReiterated RatingBuyLow
i
Rating by Joseph Schwartz at SVB Leerink LLC
9/3/2019JPMorgan Chase & Co.Boost Price TargetOverweight$39.00 ➝ $49.00Medium
i
Rating by Jessica Fye at JPMorgan Chase & Co.
9/3/2019OppenheimerBoost Price TargetOutperform$52.00 ➝ $60.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/3/2019CitigroupBoost Price TargetBuy ➝ Buy$48.00 ➝ $55.00High
i
9/2/2019Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$142.00 ➝ $145.00High
i
8/26/2019B. RileySet Price TargetBuy$61.00Low
i
Rating by Mayank Mamtani at B. Riley
8/26/2019Chardan CapitalSet Price TargetBuy$90.00Low
i
Rating by Gbola Amusa at Chardan Capital
8/26/2019Roth CapitalSet Price TargetBuy$72.00Low
i
Rating by Yasmeen Rahimi at Roth Capital
8/26/2019CowenSet Price TargetBuy$48.00Low
i
Rating by Chris Shibutani at Cowen Inc
8/26/2019JPMorgan Chase & Co.Set Price TargetBuy$39.00Low
i
Rating by Jessica Fye at JPMorgan Chase & Co.
8/26/2019Bank of AmericaReiterated RatingBuy$51.00High
i
8/4/2019CowenSet Price TargetBuy$46.00Low
i
Rating by Chris Shibutani at Cowen Inc
7/15/2019OppenheimerSet Price TargetBuy$48.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/9/2019Bank of AmericaReiterated RatingBuy ➝ Buy$36.00 ➝ $43.00Medium
i
5/28/2019B. RileySet Price TargetBuy$61.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/20/2019B. RileySet Price TargetBuy$38.00Low
i
Rating by Mayank Mamtani at B. Riley
5/20/2019Robert W. BairdReiterated RatingOverweight$80.00 ➝ $110.00High
i
4/26/2019Chardan CapitalReiterated RatingBuy ➝ Buy$85.00 ➝ $90.00High
i
4/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$25.00 ➝ $55.00High
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
3/27/2019Robert W. BairdInitiated CoverageOutperform$80.00High
i
3/21/2019Roth CapitalInitiated CoverageBuy ➝ Buy$75.00 ➝ $75.00Low
i
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
i
12/13/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00High
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
11/11/2018CowenSet Price TargetBuy$46.00High
i
Rating by Chris Shibutani at Cowen Inc
11/9/2018OppenheimerSet Price TargetBuy$50.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/24/2018OppenheimerSet Price TargetBuy$50.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/20/2018CitigroupBoost Price TargetBuy ➝ Buy$40.00 ➝ $50.00Low
i
8/16/2018OppenheimerSet Price TargetBuy$50.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/7/2018B. RileyInitiated CoverageBuy$55.00High
i
3/22/2018OppenheimerReiterated RatingBuyLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/12/2018OppenheimerSet Price TargetBuy$50.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/23/2018Jefferies Financial GroupReiterated RatingBuy$47.00Low
i
2/22/2018OppenheimerSet Price TargetHold$50.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/24/2018Chardan CapitalReiterated RatingBuy$85.00High
i
Rating by Gbola Amusa at Chardan Capital
1/24/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$45.00High
i
1/22/2018CitigroupUpgradeNeutral ➝ Buy$40.00High
i
1/15/2018OppenheimerSet Price TargetBuy$50.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/30/2017CitigroupUpgradeSell ➝ OutperformHigh
i
11/29/2017OppenheimerUpgradeMarket Perform ➝ Buy$50.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/26/2017OppenheimerSet Price TargetHold$50.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/26/2017Jefferies Financial GroupReiterated RatingBuy$54.00N/A
i
10/23/2017GuggenheimInitiated CoverageBuy$45.00N/A
i
10/4/2017OppenheimerSet Price TargetHold$50.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/20/2017Chardan CapitalReiterated RatingBuy$85.00Low
i
Rating by Gbola Amusa at Chardan Capital
9/14/2017Jefferies Financial GroupReiterated RatingBuy$54.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/29/2017Chardan CapitalReiterated RatingBuy ➝ Buy$80.00 ➝ $85.00High
i
8/17/2017OppenheimerSet Price TargetHold$50.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/14/2017CitigroupLower Price TargetNeutral$45.00 ➝ $44.00Low
i
8/10/2017Jefferies Financial GroupReiterated RatingBuy$62.00 ➝ $54.00High
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/10/2017CowenReiterated RatingBuy$61.00 ➝ $54.00High
i
7/26/2017CitigroupBoost Price TargetNeutral$43.00 ➝ $45.00Low
i
7/17/2017CitigroupLower Price TargetNeutral$59.00 ➝ $43.00Medium
i
6/28/2017Jefferies Financial GroupReiterated RatingBuy$62.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/23/2017CIBCSet Price Target$50.00Medium
i
5/22/2017OppenheimerInitiated CoverageMarket Perform$50.00Low
i
4/19/2017CowenBoost Price TargetOutperform$39.00 ➝ $61.00Low
i
4/12/2017Jefferies Financial GroupReiterated RatingBuy$62.00Low
i
3/20/2017HC WainwrightReiterated RatingBuy$60.00High
i
Rating by E. Arce at HC Wainwright
3/18/2017JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
Rating by Jessica Fye at JPMorgan Chase & Co.
3/1/2017Jefferies Financial GroupBoost Price TargetPositive$49.00 ➝ $62.00N/A
i
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/A
i
2/27/2017HC WainwrightReiterated RatingBuy$57.00 ➝ $60.00N/A
i
Rating by E. Arce at HC Wainwright
1/8/2017Chardan CapitalReiterated RatingBuy$65.00N/A
i
1/6/2017Jefferies Financial GroupReiterated RatingPositive$49.00N/A
i
12/5/2016HC WainwrightInitiated CoverageBuy$57.00N/A
i
Rating by E. Arce at HC Wainwright
11/18/2016GuggenheimReiterated RatingBuyN/A
i
11/16/2016Royal Bank of CanadaBoost Price TargetOutperform$45.00 ➝ $52.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
11/16/2016Jefferies Financial GroupReiterated RatingBuy$43.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
11/8/2016SVB LeerinkReiterated RatingOutperform$53.00 ➝ $50.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
11/8/2016Royal Bank of CanadaReiterated RatingOutperform$48.00 ➝ $45.00N/A
i
11/8/2016Royal Bank of CanadaLower Price TargetOutperform$48.00 ➝ $45.00N/A
i
Rating by Adnan Butt at Royal Bank of Canada
10/8/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
10/7/2016Jefferies Financial GroupReiterated RatingBuy$43.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/6/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
8/31/2016Jefferies Financial GroupReiterated RatingBuy$43.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/15/2016GuggenheimReiterated RatingBuy$55.00N/A
i
8/5/2016CowenReiterated RatingBuy$45.00N/A
i
Rating by Chris Shibutani at Cowen Inc
8/2/2016CitigroupReiterated RatingHoldN/A
i
7/27/2016GuggenheimBoost Price TargetBuy$45.00 ➝ $55.00N/A
i
7/19/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
7/12/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Adnan Butt at Royal Bank of Canada
7/12/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Tazeen Ahmad at Bank of America Co.
6/23/2016SVB LeerinkReiterated RatingBuy$53.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
6/15/2016Jefferies Financial GroupReiterated RatingBuy$43.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/2/2016Chardan CapitalReiterated RatingBuyN/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
5/14/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/10/2016CowenReiterated RatingBuyN/A
i
Rating by Chris Shibutani at Cowen Inc
5/6/2016Jefferies Financial GroupReiterated RatingBuy$44.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/5/2016CowenInitiated CoverageOutperform$45.00N/A
i
4/19/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
4/16/2016SVB LeerinkReiterated RatingOutperformN/A
i
(Data available from 4/14/2016 forward)
The Medicines logo
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $84.90
$84.90
$84.90

50 Day Range

MA: $84.90
$84.90
$84.90

52 Week Range

Now: $84.90
$17.81
$84.98

Volume

N/A

Average Volume

9,546,600 shs

Market Capitalization

$6.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of The Medicines?

The following Wall Street research analysts have issued stock ratings on The Medicines in the last twelve months:
View the latest analyst ratings for MDCO.

What is the current price target for The Medicines?

0 Wall Street analysts have set twelve-month price targets for The Medicines in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for The Medicines in the next year.
View the latest price targets for MDCO.

What is the current consensus analyst rating for The Medicines?

The Medicines currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for MDCO.

What other companies compete with The Medicines?

How do I contact The Medicines' investor relations team?

The Medicines' physical mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company's listed phone number is 973-290-6000 and its investor relations email address is [email protected] The official website for The Medicines is www.themedicinescompany.com.